To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
CHDI Licenses Redistribution® Technology
CHDI, Inc. and Fisher BioImage ApS (BioImage) have announced that CHDI has licensed BioImage's Redistribution® technology as a primary tool in its research and development efforts.
CHDI will use Redistribution-based assays to monitor the intracellular translocation of Huntingtin and other molecules that play essential roles in Huntington Disease.
Abnormal localization of these molecules in neuronal tissues is one of the factors that has been associated with the development and progression of HD.
"Our scientists have found that translocation of key proteins involved in HD plays an integral role in the pathophysiology of the disease," said Dr. Robert Pacifici, chief scientific adviser to CHDI.
"Assays based on tracking these translocations provide an excellent tool for various phases of our research on HD, and Redistribution technology is a logical tool for us to use."
Dr. Len Pagliaro, vice president of business development at Fisher BioImage, added, "CHDI's licensing of BioImage's Redistribution technology is an excellent example of the contribution our cell-based translocation assay approach can make to challenging therapeutic areas such as HD."
"We are delighted to have reached this agreement with CHDI and we look forward to working with them."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
